DeepMed Research

Jonsson Comprehensive Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.cancer.ucla.edu

Clinical Trials

CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 1

Withdrawn

Conditions: Recurrent Multiple Myeloma
Refractory Multiple Myeloma

Interventions: Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Procedure: Computed Tomography
Drug: Cyclophosphamide
Procedure: Echocardiography
Drug: Fludarabine
Other: Fludeoxyglucose F-18
Other: Immunotherapy
Procedure: Leukapheresis
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography

First Posted Date: 2023-07-18

Last Posted Date: 2024-05-01

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT05950113

Locations: 🇺🇸
Melanie Ayala Ceja, Los Angeles, California, United States

Red Blood Cell Transfusion Thresholds for Improved Quality of Life for Patients Undergoing a Pancreatectomy for Pancreatic Cancer

Early Phase 1

Suspended

Conditions: Resectable Pancreatic Carcinoma

Interventions: Biological: Arm I Packed Red Blood Cell Transfusion (Hgb < 7 g/dL)
Biological: Arm II Packed Red Blood Cell Transfusion (Hgb < 9 g/dL)
Procedure: Computed Tomography
Procedure: X-Ray Imaging
Procedure: Biospecimen Collection
Other: Survey Administration
Procedure: Pancreatectomy

First Posted Date: 2023-05-03

Last Posted Date: 2025-03-20

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 10

Registration Number: NCT05841706

Locations: 🇺🇸
University of California at Los Angeles, Los Angeles, California, United States

Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer

Phase 2

Recruiting

Conditions: Renal Pelvis and Ureter Urothelial Carcinoma

Interventions: Procedure: Biopsy
Procedure: Biospecimen Collection
Drug: Enfortumab Vedotin
Procedure: MR Urography
Procedure: Nephroureterectomy
Biological: Pembrolizumab

First Posted Date: 2023-03-20

Last Posted Date: 2024-12-24

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 21

Registration Number: NCT05775471

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia

Phase 1

Withdrawn

Conditions: Acute Myeloid Leukemia

Interventions: Biological: Tagraxofusp-erzs
Drug: Azacitidine

First Posted Date: 2023-02-09

Last Posted Date: 2024-03-08

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT05720988

Locations: 🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸
Habtemariam,Bruck, Los Angeles, California, United States

Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

Phase 1

Recruiting

Conditions: Borderline Resectable Pancreatic Adenocarcinoma
Locally Advanced Pancreatic Ductal Adenocarcinoma

Interventions: Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Core Biopsy
Drug: Fluorouracil
Drug: Irinotecan
Drug: Leucovorin
Drug: Leucovorin Calcium
Drug: Oxaliplatin
Drug: Quemliclustat
Drug: Zimberelimab

First Posted Date: 2023-01-18

Last Posted Date: 2025-05-06

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 56

Registration Number: NCT05688215

Locations: 🇺🇸
Yonemoto,Lisa, Los Angeles, California, United States

Fisetin to Improve Physical Function in Stage I-III Breast Cancer Survivors

Phase 2

Recruiting

Conditions: Anatomic Stage I Breast Cancer AJCC v8
Anatomic Stage II Breast Cancer AJCC v8
Anatomic Stage III Breast Cancer AJCC v8

Interventions: Procedure: Biospecimen Collection
Drug: Placebo Administration
Drug: Fisetin
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2022-10-27

Last Posted Date: 2025-05-13

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 88

Registration Number: NCT05595499

Locations: 🇺🇸
UCLA Health Cancer Care in Alhambra, Alhambra, California, United States
🇺🇸
UCLA Health Beverly Hills Primary & Specialty Care, Beverly Hills, California, United States
🇺🇸
UCLA Health Burbank Primary & Specialty Care, Burbank, California, United States

and more 4 locations

An Investigational Scan (Me-4FDG PET/CT) for the Detection of Sodium-Glucose Transport for Early Diagnosis of Lung Cancer

Phase 1

Recruiting

Conditions: Lung Adenocarcinoma

Interventions: Drug: Alpha-methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside
Procedure: Computed Tomography
Other: Laboratory Biomarker Analysis
Procedure: Positron Emission Tomography

First Posted Date: 2022-09-28

Last Posted Date: 2025-02-24

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 60

Registration Number: NCT05558904

Locations: 🇺🇸
Yesenia Calzada, Los Angeles, California, United States

Value-based Integrated Recommendation Software Guiding Ovarian Cancer Treatment (VIRGO2)

Not Applicable

Recruiting

Conditions: Ovarian Cancer

Interventions: Other: Mobile Application

First Posted Date: 2022-08-31

Last Posted Date: 2025-01-09

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 200

Registration Number: NCT05523700

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study

Phase 2

Active, not recruiting

Conditions: Oligometastatic Prostate Carcinoma
Prostate Adenocarcinoma
Recurrent Prostate Adenocarcinoma
Stage IVB Prostate Cancer AJCC v8

Interventions: Other: Quality-of-Life Assessment
Drug: Lutetium Lu-177 PNT2002
Radiation: Stereotactic Body Radiation Therapy

First Posted Date: 2022-08-11

Last Posted Date: 2025-05-13

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 93

Registration Number: NCT05496959

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant

Phase 1

Withdrawn

Conditions: Diffuse Hemispheric Glioma, H3 G34-Mutant

Interventions: Biological: Ipilimumab
Biological: Dendritic Cell Tumor Peptide Vaccine
Procedure: Leukapheresis
Drug: Placebo Administration
Biological: Nivolumab
Drug: Poly ICLC
Procedure: Resection

First Posted Date: 2022-07-14

Last Posted Date: 2025-02-24

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 15

Registration Number: NCT05457959

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy